A Rndomised Control Trial to Compare LAMA-LABA vs. LABA-ICS in Bronchiectaisis

A Randomised Trial to Compare The Efficacy and Safety of LABA LAMA vs. LABA ICS in Non-Cystic Fibrosis Bronchiectasis - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105875

Enrollment

110

Registered

2026-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J479- Bronchiectasis, uncomplicated

Interventions

Intervention1: LAMA LABA: Formoterol furoate 12 mcg Glycopyrronium 25 mcg will be given for 6 months duration Control Intervention1: LABA ICS: Formoterol furoate 12 mcg Fluticasone 250 mcg will be giv

Eligibility

Inclusion criteria

Inclusion criteria: Bronchiectasis confirmed on the high-resolution computed tomography of the thorax. Clinical syndrome of cough, expectoration, breathlessness, or recurrent respiratory infections Treatment naÃ¯ve patients

Exclusion criteria

Exclusion criteria: 1. Bronchiectasis secondary to bronchial asthma, allergic bronchopulmonary aspergillosis, chronic obstructive pulmonary disease, cystic fibrosis 2. Patients on oral corticosteroids for other reasons 3. Acute exacerbation within the last 4 weeks 4. Pregnant or breastfeeding individuals 5. Failure to provide informed consent

Design outcomes

Primary

Measure	Time frame
Change in post Bronchodilator FEV1Timepoint: 6 months	—

Secondary

Measure	Time frame
Health related quality of lifeTimepoint: 6 months;Dyspnea improvementTimepoint: 6 months;exacerbationsTimepoint: 6 months;treatment escalationTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Murtuza Shujaat Hashmi

AIIMS Mangalagiri

damarajuvikram@aiimsmangalagiri.edu.in9501482884

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026